targeted therapies in aml: menin, flt3 and idh inhibitors
Published 3 months ago • 171 plays • Length 5:20Download video MP4
Download video MP3
Similar videos
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
1:56
promising targets beyond flt3 in aml: idh1/2 & menin
-
3:14
flt3 mutations for targeted therapy in aml
-
2:29
combining menin/flt3/bcl2 inhibition as a treatment approach in flt3/npm1 double mutated aml
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
2:29
flt3 inhibitors as maintenance therapy in aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:32
novel treatment combinations for flt3-mutated aml
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
6:43
flt3 mutations’ impact on prognosis and treatment in aml
-
10:23
my acute myeloid leukemia (aml) relapse story
-
4:47
the use of flt3 inhibitors in aml
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
2:08
comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
-
1:40
sf3b1 as therapeutic target in flt3/itd positive aml
-
1:06
investigating the molecular and clinical features of flt3-jmd mutations in aml
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
1:36
targeted therapy for aml
-
1:04
continuous treatment with flt3 inhibitors for patients with flt3-mutated aml undergoing allosct
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
1:33
clinical trials investigating treatment approaches for flt3-mutated and idh-mutated aml patients
-
2:55
the importance of flt3 inhibitors in aml and factors to consider when choosing between these agents